PM 54
Alternative Names: PM-54Latest Information Update: 14 Oct 2025
At a glance
- Originator PharmaMar
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants; RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 14 Oct 2025 PM 54 is still in phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Monotherapy) in Belgium, USA and Spain (IV) (NCT05841563) (PharmaMar pipeline; October 2025)
- 25 Apr 2025 Pharmacodynamics data from the preclinical trial in Solid tumours presented at the 16th Annual Meeting of the American Association for Cancer Research 2025 (AACR-2025)
- 24 Mar 2025 PharmaMar initiates a phase-I trial in Solid tumours (Late-stage disease) in Spain (Unspecified) (CTIS2024-517579-19-00)